We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/0008-5472.CAN-05-2856 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive method for producing high-affinity mouse monoclonal antibodies of various isotypes against (4-hydroxy-3-nitrophenyl)acetyl (NP) hapten.
Heliyon
December 2024
Department of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Monoclonal antibody (mAb) technology has significantly contributed to basic research and clinical settings for various purposes, including protective and therapeutic drugs. However, a rapid and convenient method to generate high-affinity antigen-specific mAbs has not yet been reported. Here, we developed a rapid, easy, and low-cost protocol for antigen-specific mAb production from single memory B cells.
View Article and Find Full Text PDFA novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy.
Acta Pharm Sin B
November 2024
College of Marine Science and Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Article Synopsis
- - TROP-2, a protein linked to various types of cancer, is a potential target for new cancer treatments, specifically antibody-drug conjugates (ADCs), but their effectiveness against solid tumors is limited due to issues like poor penetration.
- - Researchers developed a small, stable immunotoxin using a shark-derived antibody known as VNAR, which has better tissue penetration properties than traditional antibodies.
- - The study identified a specific VNAR, called VNAR-5G8, which binds effectively to TROP-2 and created a recombinant immunotoxin (5G8-PE38) that showed strong anti-tumor activity, suggesting its potential as a cancer therapy option.
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology.
Immunol Rev
November 2024
Université Paris Saclay, Le Kremlin-Bicetre, France.
Antagonistic monoclonal antibodies (mAbs) targeting inhibitory immune checkpoints have revolutionized the field of oncology. CTLA-4, PD-1, and LAG3 are three co-inhibitory receptors, which can be expressed by subsets of T cells and which play a role in the regulation of adaptive immune responses. Blocking these immune checkpoints receptors (or their ligands) with antagonistic antibodies can lead to tumor regressions and lasting remissions in some patients with cancer.
View Article and Find Full Text PDFA Competition-Based Strategy for the Isolation of an Anti-Idiotypic Blocking Module and Fine-Tuning for Conditional Activation of a Therapeutic Antibody.
Biotechnol J
December 2024
Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Hesse, Germany.
The masking of therapeutic antibodies by the installation of a blocking module that can be removed under certain physiological conditions, is becoming increasingly important to improve their safety and toxicity profile. To gain access to such masking units, we used chicken immunization in combination with yeast surface display and a competition-based FACS screening campaign to obtain anti-idiotypic single-chain Fv (scFv) fragments. This approach promotes the identification of functional masking units, since specificity and high affinity do not necessarily guarantee a paratope blocking effect.
View Article and Find Full Text PDFTranslational population target binding model for the anti-FcRn fragment antibody efgartigimod.
J Pharmacokinet Pharmacodyn
December 2024
Argenx BV, Industriepark Zwijnaarde 7, Zwijnaarde, 9052, Belgium.
Efgartigimod is a human IgG1 antibody Fc-fragment that lowers IgG levels through blockade of the neonatal Fc receptor (FcRn) and is being evaluated for the treatment of patients with severe autoimmune diseases mediated by pathogenic IgG autoantibodies. Engineered for increased FcRn affinity at both acidic and physiological pH, efgartigimod can outcompete endogenous IgG binding, preventing FcRn-mediated recycling of IgGs and resulting in increased lysosomal degradation. A population pharmacokinetic-pharmacodynamic (PKPD) model including FcRn binding was developed based on data from two healthy volunteer studies after single and repeated administration of efgartigimod.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!